The ProGRESS Study is a randomized clinical trial. Participants will be mailed a saliva collection kit to their home, to collect DNA. The saliva DNA sample will be shipped to our partnering lab, Broad Clinical Labs, which will analyze the DNA for genetic markers related to prostate cancer risk. All participants will be randomly divided into two groups (like the flip of a coin): 

• Standard of care prostate cancer screening: These participants will receive standard information about prostate cancer screening and shared decision-making to share with their healthcare providers.     

• Precision prostate cancer screening: These participants will receive personalized prostate cancer screening recommendations tailored to their level of genetic risk.   These results will be sent to the participants and their healthcare providers.

ProGRESS hopes to find that precision prostate cancer screening through genetic testing can help identify men at a higher risk for developing clinically significant prostate cancer, decrease the number of unnecessary biopsies, and deliver an equitable precision prostate cancer screening strategy that improves health outcomes for all men.